BLCO - Bausch + Lomb Corporation

NYSE - Nasdaq Real-time price. Currency in USD
17.94
-0.47 (-2.55%)
At close: 04:00PM EDT
17.94 0.00 (0.00%)
After hours: 04:56PM EDT
Stock chart is not supported by your current browser
Previous close18.41
Open18.38
Bid17.17 x 800
Ask18.68 x 900
Day's range17.83 - 18.50
52-week range12.20 - 19.96
Volume271,389
Avg. volume389,877
Market cap6.309B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

    VAUGHAN, Ontario & HEIDELBERG, Germany, May 18, 2023--FDA approves MIEBO (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease.

  • Business Wire

    Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance

    VAUGHAN, Ontario, May 03, 2023--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2023 financial results.

  • Business Wire

    Bausch + Lomb Releases Annual Environmental, Social and Governance Report

    VAUGHAN, Ontario, May 01, 2023--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today released its annual Environmental, Social and Governance (ESG) Report, highlighting the Company’s ongoing commitment to implement sustainable business practices and initiatives that support its stakeholders’ well-being.

  • Business Wire

    Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

    VAUGHAN, Ontario, April 26, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 podium presentations and four poster presentations related to the company’s products and pipeline programs during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place in San Diego from May 5-8, 2023.

  • Business Wire

    Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results

    VAUGHAN, Ontario, April 25, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2023 annual meeting of shareholders (the "Annual Meeting") held on April 24, 2023. The detailed results of the vote for the election of directors are set out below:

  • Business Wire

    Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

    VAUGHAN, Ontario, April 24, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System. StableVisc and TotalVisc provide eye surgeons with new options for dual-action protection during cataract surgery.

  • Business Wire

    Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

    VAUGHAN, Ontario, April 20, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of eight scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in New Orleans from April 23-27, 2023.

  • Business Wire

    Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs

    VAUGHAN, Ontario, April 18, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 65.8 million units, or 397,194 pounds, of used contact lenses, eye care and lens care materials, which is equivalent to the weight of three commercial-sized airplanes.

  • Business Wire

    Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3

    VAUGHAN, Ontario, April 17, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2023 financial results on Wednesday, May 3, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website pr

  • Business Wire

    Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform

    VAUGHAN, Ontario & HEIDELBERG, Germany, April 13, 2023--Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, and Heidelberg Engineering, today announced the introduction of the SeeLuma™ Fully Digital Surgical Visualization Platform, which provides ophthalmic surgeons with a new level of visualization compared to optical, hybrid and retrofitted microscopes. Developed to facilitate even the most complex surgical procedures, SeeLuma will be intro

  • Business Wire

    Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals

    VAUGHAN, Ontario, April 12, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company. Concurrent with these

  • Business Wire

    Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

    VAUGHAN, Ontario & HEIDELBERG, Germany, March 22, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in class ocular therapeutics, today announced that American Journal of Ophthalmology has published results from MOJAVE, the second pivotal Phase 3 trial for NOV03 (perfluorohexyloctane). NOV03 is being investigated to

  • Business Wire

    Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results

    VAUGHAN, Ontario, February 22, 2023--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2022 financial results.

  • Business Wire

    Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

    VAUGHAN, Ontario, February 15, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer ("CEO") and chair of the Board of Directors ("Board") of the Company, effective March 6, 2023. Concurrent with this appointment, and as previously announced, Joseph C. Papa will step down from his roles as CEO and director

  • Business Wire

    New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients

    VAUGHAN, Ontario, February 07, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced a new social media campaign designed to raise awareness of Age-related Macular Degeneration (AMD), a leading cause of vision loss for those over age 501 and the leading cause of blindness for the 65+ population2. The campaign, ‘What Sight Inspires You’, will feature personal stories and sights

  • Business Wire

    Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)

    VAUGHAN, Ontario & TAMPERE, Finland, February 01, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Modulight Corporation ("Modulight"), a biomedical laser company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) photodynamic therapy (PDT) for the

  • Business Wire

    Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22

    VAUGHAN, Ontario, January 23, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial results on Wednesday, Feb. 22, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausc

  • Business Wire

    Bausch + Lomb Acquires AcuFocus, Inc.

    VAUGHAN, Ontario & IRVINE, Calif., January 17, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. ("AcuFocus"), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.

  • Business Wire

    Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

    VAUGHAN, Ontario, January 09, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of PreserVision® AREDS 2 Formula mini soft gels with OCUSorb™. This product is the only AREDS 2 eye vitamin with the OCUSorb formulation. Offering a proprietary composition of lutein and zeaxanthin, OCUSorb has been clinically shown to provide superior absorption of these

  • Business Wire

    Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference

    VAUGHAN, Ontario, January 09, 2023--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, has published a company update presentation designed to complement remarks that will be provided by management at 3:00 p.m. PT (6:00 p.m. ET) today, Jan. 9, 2023, during the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation provides an overview of the Company’s

  • Business Wire

    Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference

    VAUGHAN, Ontario, January 05, 2023--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that Joseph C. Papa, chief executive officer, and Sam Eldessouky, executive vice president and chief financial officer, are scheduled to participate at the 41st Annual J.P. Morgan Healthcare Conference on Jan. 9, 2023, at 3:00 p.m. PT (6:00 p.m. ET).

  • Business Wire

    Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

    VAUGHAN, Ontario & HEIDELBERG, Germany, January 04, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in class ocular therapeutics, today announced that Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, has published results from the pivotal Phase 3 trial GOBI, which is one of two pi

  • Business Wire

    Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month

    VAUGHAN, Ontario, January 03, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national non-profit organization with the vision of curing glaucoma, today announced the U.S. launch of ‘Screen, Protect, Cure,’ a campaign designed to provide educational resources and raise awareness of glaucoma, a leading cause of irreversible blindness, during Glau

  • PR Newswire

    Bausch + Lomb Amends CEO Separation Agreement

    Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced that the Company and its CEO, Joseph C. Papa, have entered into an Amended and Restated Separation Agreement (the "Amended Separation Agreement"), pursuant to which Mr. Papa has agreed to continue serving as CEO until at least March 4, 2023 and lasting until such date as the Board of Directors of the Company dete

  • PR Newswire

    Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops

    Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses.